Summary of Interim Report January - June 2021, Dicot AB

Press release: Uppsala, August 25, 2021. A summary of the Interim report January - June 2021, for Dicot AB (publ) is now available on the company website 

Second quarter 2021

  • Net sales amounts to KSEK 33 (0)
  • Earnings for the period amounts to KSEK -5,503 (-3,152).
  • Earnings per share SEK -0.09 (-0.18)

January - June 2021

  • Net sales amounts to KSEK 69 (0)
  • Earnings for the period amounts to KSEK -13,971 (-9,724).
  • Earnings per share SEK -0.26 (-0.57)

Statement from the CEO

After a winter and spring with intensive development work, we recently got the results from our effect studies performed in collaboration with Pelvipharm in France. The studies show that the effect of LIB-01 lasts for at least seven days. This is a major breakthrough for Dicot.

DICOT'S AMBITION is to develop a leading drug to treat erectile dysfunction. This means that our future product needs to display unique features which are better than the treatments available today, where long-term effect perhaps is the foremost.

PROFESSOR JARL WIKBERG that founded Dicot in 2016 showed in his early animal studies that LIB-01 has longer effect than treatments on the market today, up to 14 days. This would eliminate the planning of sexual activities as compared to existing treatments having a relatively short-term effect.

IN ORDER TO GET APPROVAL TO START CLINICAL TRIALS data from the early academic research needs to be complemented with data from well-established and validated animal models. During the spring, we have therefore continued to work with Pelvipharm and can now report truly gratifying results. The effect of LIB-01 lasts for at least seven days and increases up until day seven. This is a major breakthrough for Dicot in the development of a new drug with a long duration of action. Professor Francois Giuliano, who is co-founder of Pelvipharm and an international authority in the field, deems that the results of these studies clearly indicate that LIB-01 works.

IT'S AN HONOR FOR ME to continue the work of Professor Jarl Wikberg and it is gratifying that the results we now present is consistent with his early academic research. The other ongoing study at Pelvipharm, performed in animals with established erectile dysfunction, will be reported during the autumn. In addition to this, further studies will be started to evaluate more doses as well as  the optimal conditions for long-term effect.. Overall, this contributes to our documentation needed to apply for starting a clinical Phase 1 study which is expected to start during next year.

DICOT NOW REINFORCES THE COMPETENCE within the company and has recruited Elin Trampe as COO and vice President. She starts in her new role 1st of September and will lead the development of the drug candidate together with our present team. Elin has a broad experience and relevant qualifications, most recently from the role as CTO at Oasmia Pharmaceutical in Uppsala. During the previous quarter, the board was also expanded with one member: Dr Per-Göran Gillberg who has extensive experience in Pharmacology and Drug Development.

WITH THE FANTASTIC RESULTS from the collaboration with Pelvipharm and the reinforced team backing us up, I have great faith in the continued work this autumn.

For further information, please contact:

Göran Beijer CEO
Tel: +46 706 63 60 09
Email: [email protected]

Jessica Roxhed, CFO
Tel: +46 70-394 94 98
Email: [email protected]

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 1,800 shareholders. For more information, please visit

Med anledning av positiva studieresultat offentliggör Dicot tilläggsprospekt

Pressmeddelande: Uppsala, 20 oktober 2021. Med anledning av att Dicot AB ("Dicot" eller "Bolaget") den 14 oktober 2021 offentliggjorde positiva resultat från en avslutad studie under den pågående teckningsperioden i Bolagets förestående företrädesemissionen av units har Bolaget nu upprättat ett tilläggsprospekt ("Tilläggsprospektet") till det EU-tillväxtprospekt som godkändes och registrerades av Finansinspektionen den 8 oktober 2021 ("Prospektet"). Tilläggsprospektet - som godkändes av Finansinspektionen idag den 20 oktober 2021 - är en del av och ska läsas tillsammans med Prospektet.

Due to positive study results Dicot publishes a supplement prospectus

Press release: Uppsala, October 20, 2021. On October 14, 2021 Dicot AB ("Dicot" or the "Company") published positive results from a completed study. Since that publication was made during the subscription period in the ongoing unit rights issue the Company has now established a supplement prospectus (the "Supplement") to the EU growth prospectus related to the invitation to subscribe for units in Dicot with preferential rights which was approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) (''SFSA'') on October 8, 2021 (hereinafter, the "Prospectus"). The Supplement - which was approved by the Swedish Financial Supervisory Authority today October 20, 2021 - forms a part of the Prospectus and shall in all respects be read together with the Prospectus.

Studie av djur med diabetes visar på effekt hos Dicots läkemedelskandidat

Pressmeddelande: Uppsala, 14 oktober 2021. Potensläkemedelsutvecklaren Dicot har precis avslutat en studie på råttor med diabetes och bevisad erektil dysfunktion. Bolagets läkemedelskandidat demonstrerade signifikant förbättrad erektion jämfört med kontrollgruppen.

Study of animals with diabetes shows effect in Dicot's drug candidate

Press release: Uppsala, October 14, 2021. Potency drug developer Dicot has just completed a study on rats with diabetes and proven erectile dysfunction. The company's drug candidate demonstrated significantly improved erections compared to vehicle.

Teckningsperioden i Dicots företrädesemission inleds idag den 12 oktober 2021

Pressmeddelande: Uppsala, 12 oktober 2021. Idag, den 12 oktober 2021, inleds teckningsperioden i Dicot ABs (publ) ("Dicot" eller "Bolaget") förestående företrädesemission av units vilken offentliggjordes den 8 september 2021 och som godkändes av extra bolagsstämman den 6 oktober 2021 ("Företrädesemissionen").

The subscription period for Dicot's rights issue begins today on October 12, 2021

Press release: Uppsala, October 12, 2021. Today on October 12, 2021, the subscription period for the rights issue in Dicot AB (publ) ("Dicot" or the "Company"), which was made public on September 8, 2021 and resolved by the extra general meeting on October 6, 2021 (the "Rights Issue") commences.

Dicot offentliggör EU-tillväxtprospekt avseende företrädesemissionen

Pressmeddelande: Uppsala, 8 oktober 2021. Dicot AB ("Dicot" eller "Bolaget") har upprättat ett EU-tillväxtprospekt (''Prospektet'') avseende Bolagets företrädesemission, vilken offentliggjordes den 8 september 2021 och som godkändes av extra bolagsstämman den 6 oktober 2021 ("Företrädesemissionen"). Prospektet har godkänts av Finansinspektionen och finns nu tillgängligt på Bolagets hemsida och kommer att göras tillgängligt på Hagberg & Aneborn Fondkommission AB:s hemsida  

Dicot publishes EU growth prospectus related to its rights issue

Press release: Uppsala, October 8, 2021. Dicot AB ("Dicot" or the "Company") has established an EU growth prospectus (the ''Prospectus'') related to the Company's rights issue, which was made public on September 8, 2021 and resolved by the extra general meeting on October 6, 2021 (the "Rights Issue"). The prospectus has now been approved by Swedish Financial Supervisory Authority and is now available at the Company's website, and will be published on Hagberg & Aneborn Fondkommission AB's website,

Kommuniké från extra bolagsstämma i Dicot AB

Dicot AB (publ) ("Bolaget") höll idag den 6 oktober 2021 extra bolagsstämma i Bolaget via poströstning varvid besluten nedan fattades.

Bodil Fornstedt Wallin, ny Project Director på Dicot

Pressmeddelande: Uppsala, 27 september 2021. Dicot AB meddelar idag att bolaget har kontrakterat Bodil Fornstedt Wallin som ny Project Director.

Rättelse: Kallelse till extra bolagsstämma i Dicot AB (PUBL)

Rättelse: med anledning av vissa emissionstekniska detaljer har tre datum avseende nyemissionen under beslutspunkt 7 nedan flyttats fram med en dag. Detta innebär att avstämningsdagen för deltagande i nyemissionen rättas  från tidigare 7 oktober 2021 till den 8 oktober 2021. Även teckningstiden för teckning av units med eller utan företrädesrätt rättas, från perioden den 11 oktober till och med den 26 oktober 2021, till perioden från och med den 12 oktober 2021 till och med den 27 oktober 2021. Kallelsen är i övrigt oförändrad från utskicket den 8 september 2021. Korrigerad kallelse i sin helhet följer nedan.

Aktieägarna i Dicot AB (publ), 559006-3490 ("Bolaget"), kallas härmed till extra bolagsstämma onsdagen den 6 oktober 2021. Mot bakgrund av risken för spridning av Covid-19 och myndigheternas föreskrifter/råd om undvikande av sammankomster har styrelsen beslutat att bolagsstämman ska genomföras utan fysisk närvaro genom att aktieägare utövar sin rösträtt endast genom poströstning. Någon fysisk sammankomst kommer således inte att hållas.

Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted